UNSPSC 51132238: Aspirin/ethoheptazine/meprobamate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

UNSPSC 51132238 Aspirin/ethoheptazine/meprobamate is a Commodity code that, based on recent state and local solicitations, encompasses pharmaceutical products and over-the-counter medications supplied through competitive procurement channels to government health agencies, community health programs, and pharmacy benefit systems. State and local governments buying under this code are sourcing generic pharmaceuticals, naloxone, and OTC products for distribution across health facilities, emergency response programs, and integrated pharmacy networks. The issuing bodies include state health and human services departments, county health programs, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Seminole County, Florida, and the Texas Health and Human Services Commission exemplify the range of buyers — from single-jurisdiction community health initiatives to statewide pharmacy benefit program reforms.

Recent activity spans Florida, Texas, and the Upper Midwest, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) representing a significant cooperative vehicle serving state and local facilities across multiple states including Oregon. Representative opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2026; the Texas HHS Commission's RFI HHS0017013, issued April 3, 2026, to assess vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and MMCAP's RFP S1070000015802, posted January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, with proposals due March 26, 2026 and performance effective July 1, 2026. MMCAP's solicitation emphasizes pricing competitiveness (75 percent of evaluation weight), cGMP and Drug Supply Chain Security Act compliance, and relationships with authorized wholesalers, signaling that scale, regulatory rigor, and supply-chain integration are core procurement drivers in this commodity space.